ArticleScientific reports2025
Detection of moderate to high antiphospholipid antibodies by chemiluminescence meets 2023 APS classification criteria.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
The 2023 ACR/EULAR criteria for antiphospholipid syndrome (APS) have modified the laboratory domain. However, enzyme-linked immunosorbent assay (ELISA) remains the sole specified method for antiphospholipid antibody detection. This study aims to establish moderate and high levels of anticardiolipin(aCL) and anti-β2-glycoprotein I antibodies (anti-β2GPI) using chemiluminescence assay (CIA) and to investigate the diagnostic efficiency and risk stratification capabilities of CIA in comparison to ELISA. We conducted a comprehensive analysis involving 166 APS patients, 194 disease controls, and 120 healthy controls. Our assessment entailed the utilization of both ELISA and CIA to detect aCL IgG/IgM and anti-β2GPI IgG/IgM. We established distinct moderate and high semi-quantitative thresholds for CIA corresponding to ELISA. Additionally, we computed the likelihood ratios at various thresholds and compared them with ELISA. The qualitative agreement and quantitative correlation between CIA and ELISA were robust. When applying the established moderate and high thresholds of aCL/aβ2GPI IgG/IgM in CIA according to the equal ROC specificity corresponding to ELISA, the diagnostic efficiency and risk stratification capabilities of CIA aligned comparably with those of ELISA. Although IgM exhibited poorer performance in risk assessment compared to IgG, it still played as risk factors for thrombosis and obstetrical manifestations. Utilizing the established moderate/high thresholds for aCL/aβ2GPI IgG/IgM by CIA, effectively addressing both diagnostic and risk stratification requirements comparable to ELISA, signifies that the CIA has emerged as an alternative for aPL detection. The high specificity and clinical relevance of aCL/aβ2GPI IgM in clinical events highlight its importance in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.